Answers are grounded in this paper and cite their sources.
Prospective multicenter investigation shows excellent mid-term patency in PAD patients, suggesting clinical viability.
The Renzan™ stent demonstrated excellent early safety and efficacy outcomes in a challenging PAD population, with sustained mid-term patency despite a high proportion of complex lesions. These preliminary results support the use of this new mimetic stent design in real-world clinical settings and warrant further confirmation with longer-term follow-up.
No takes yet. Share an insight, caveat, or question.
DONATO et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: